ABSTRACT

Objectives: In 2003, a skin cancer screening campaign based on total body skin examination was launched in the federal state of Schleswig-Holstein, Germany. 20% of adults aged 20 and over were screened. In 2008, a 48% decline in melanoma mortality was reported. In the same year, skin screening was extended to the rest of Germany. We evaluated whether melanoma mortality trends decreased in Germany as compared with surrounding countries where skin screening is uncommon. We also evaluated whether the initial decreasing mortality trend observed in Schleswig-Holstein was maintained with a longer follow-up.

Setting and participants: Regional and national melanoma mortality data from 1995 to 2013 were extracted from the GEKID database and the Federal Statistical Office. Mortality data for Germany and surrounding countries from 1980 to 2012 were extracted from the WHO mortality database.

Primary and secondary outcome measures: Age-adjusted (European Standard Population) mortality rates were computed and joinpoint analysis performed for Schleswig-Holstein, Germany and surrounding countries.

Results: In Schleswig-Holstein, melanoma mortality rates declined by 48% from 2003 to 2008, and from 2009 to 2013 returned to levels observed before screening initiation. During the 5 years of the national programme (2008–2012), melanoma mortality rates increased by 2.6% (95% CI −0.1 to 5.2) in men and 0.02% (95% CI −1.8 to 1.8) in women. No inflexion point in trends was identified after 2008 that could have suggested a decreasing melanoma mortality. Trends of cutaneous melanoma mortality in Germany from 1980 to 2012 did not differ from those observed in surrounding countries.

Conclusions: The transient decrease mortality in Schleswig-Holstein followed by return to pre-screening levels could reflect a temporal modification in the reporting of death causes. An in-depth evaluation of the screening programme is required.

INTRODUCTION

Many public health agencies like the United States Preventive Services Task Force (USPSTF) or the National Institute for Health and Care Excellence (NICE) in the UK do not recommend skin cancer screening. This practice, however, tends to increase: 14.5% of adults in the USA in 2000 had at least one total body skin examination (TBSE), this figure increased to 19.8% in 2010.1

In 2003, a skin cancer screening campaign (the SCREEN (Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany) project) was initiated in the federal state of Schleswig-Holstein in Germany.2 This campaign was based on TBSE offered from July 2003 to June 2004 to individuals aged 20 and over by dermatologists and by non-dermatologist practitioners who had followed an 8 h training course. These TBSE were fully covered by health insurances; physicians received a financial incentive of €15 per screening. No invitation or follow-up system was implemented, but the population was informed about the campaign by a large-scale mass media...
changes (APC) in mortality were then computed for the period 1980–2012, and for the period 2008–2012, that is for the 5 years following the introduction of screening in Germany.

Temporal trends of melanoma mortality were analysed from 1980 to 2012 in Germany and surrounding countries using joinpoint regression. Joinpoint software fits a series of straight lines connected on a common point, called ‘joinpoint’, on a logarithmic scale to the annual age-standardised rates. The selected number of lines and points of inflexion, if any, is based on the simplest model that the data allow. The programme uses permutation analysis with a grid search algorithm to identify inflexions in trends with an overall statistical significance level of 0.05. We kept default settings in the programme, that is, allowing up to five possible joinpoints during 1980–2012, with three observations from a joinpoint to either end of the data and four observations between two joinpoints. We reported trends for the last uninterrupted segment identified in the joinpoint regression by age groups: less than 60, 60–74, and 75 and over.

RESULTS
Melanoma mortality in Schleswig–Holstein
Melanoma mortality dropped in the years immediately following the pilot project that took place in 2001 (figure 1). In 2008, melanoma mortality rates were well below the rates reported for Germany. In 2009–2010, a doubling of mortality rates took place, and in 2012 and 2013, the melanoma rates were close to the rates observed before the pilot project.

Melanoma incidence and mortality in Germany
Schleswig–Holstein has a population size of 2 806 000 people, it represents 3.5% of all Germany. In Schleswig–Holstein before the SCREEN project started (1998–1999), the age-standardised melanoma mortality rate (World Standard Population) was 1.9 per 100 000 for men and 1.4 per 100 000 for women. Melanoma mortality declined by 47% to 1.0 per 100 000 men and by 49% to 0.7 per 100 000 women by 2008/2009. The APC in the period 2000–2009 was −7.5% (95% CI −14.0 to −0.5) for men and −7.1% (95% CI −10.5 to −2.9) for women. In each of the four adjacent regions and in the rest of Germany, the mortality rates were stable.

Overall, in Germany, the average participation rate in the skin cancer screening programme from January 2009 to December 2010 reached 30.8%. The launch of the national screening programme was immediately followed by a 29% rise in the incidence of cutaneous melanoma in both sexes (figure 2), from about 14.5 cases per 100 000 person-years in 2006 to 18.0 cases per 100 000 person-years in 2010.

From 1980 to 2012, the melanoma mortality rate in Germany remained flat with an APC of 0.44% in men and −0.15% in women (table 1).

In the 5-year period following the introduction of the national screening programme, melanoma mortality...
rates increased by 2.60% in men and 0.02% in women. Hence, upward trends were more marked in the years after screening introduction than during the whole period. The joinpoint analysis did not identify a change in trends after 2008 that could have suggested some downward inflexion in mortality. The last inflexion in men was observed in 1996 followed by a monotonic significant increase in mortality of 0.8% (95% CI 0.4 to 1.3; figure 3). In women, the last downward inflexion was observed in 1997, also followed by a monotonic significant increase of 0.4% (95% CI 0.0 to 0.8).

**Comparison with surrounding countries**

For men and women, trends in melanoma mortality in Germany did not differ from trends in surrounding countries (figure 3). No decline in melanoma mortality was observed in the surrounding countries, except in Austrian women in whom a decline of −0.9% per year (95% CI −1.8% to −0.0%) took place after 1994. Analysis of trends by age group (table 2) did not indicate any particular difference in most recent trends in Germany and in surrounding countries.

**DISCUSSION**

The decline in melanoma mortality reported in the 5 years immediately following the start of the SCREEN project in Schleswig–Holstein was transient and during the next 5 years, rates returned to levels prevailing prior to the introduction of screening. Introduction of
screening in Germany led to significant increases in the number of diagnoses of cutaneous melanoma similar to increases reported in Schleswig–Holstein after the introduction of the SCREEN project.\textsuperscript{5} In the German study, invasive melanoma diagnoses increased by 53\% in women in Schleswig–Holstein with screening, compared with 18\% in another city, Saarland, which had no screening. A similar effect was observed in men with a 26\% increase in Schleswig–Holstein compared with 10\% in Saarland.\textsuperscript{15} But contrary to Schleswig–Holstein where melanoma mortality decreased in the five years after introduction of screening, trends in melanoma mortality in the whole of Germany did not decrease in years following introduction of screening. In addition, mortality trends in Germany in recent years did not differ from those in surrounding countries.

There is currently no systematic comprehensive evaluation of the skin cancer screening programme in Germany. Data needed for a proper understanding of differences between the SCREEN project and the national screening programme are lacking. Several factors suggest that the national programme was more intense with a higher participation rate than in the SCREEN project. In contrast, the screening period of the SCREEN project only lasted 12 months. In view of initial results of the SCREEN project, some decline in melanoma mortality for all of Germany should have been observed in the years immediately following the introduction of the national skin cancer screening programme. It could be argued that more years of observation are needed before an impact on melanoma mortality could show up. If the latter argument is considered valid, then the likelihood of the 48\% reduction in melanoma mortality in 2003–2008 reported for Schleswig–Holstein is questionable: in fact, both mortality reduction and its association with screening are questionable. In addition, the return in 2012–2013 to melanoma mortality rates prevailing before the start of the screening campaign further questions the likelihood of the transient drop in mortality reported for Schleswig–Holstein. The issue of lead time is central to the interpretation of these data. It has been estimated that it would take at least 5–7 years for an effective screening programme to potentially decrease mortality.\textsuperscript{16} Additional elements raise scepticism about the likelihood of the SCREEN project results.\textsuperscript{7,17} For instance, a low 20\% participation in screening and a high 48\% reduction in melanoma mortality are hardly compatible. The decline in melanoma mortality actually started 2 years before the launch of the SCREEN project, which cast doubt on whether skin screening was the actual cause for mortality reductions.

The analysis of impact of skin cancer screening in Germany and in particular in Schleswig–Holstein would benefit from data on trends in melanoma incidence by stage. Unfortunately, such data are not systematically reported to cancer registries in Germany. Even in Schleswig–Holstein, covered by a cancer registry of good quality, a study between 2000 and 2008 showed that 69.5\% of melanoma cases have an unknown Union for International Cancer Control (UICC) stage.\textsuperscript{18} In view of these elements, skin cancer screening is most probably not the cause of the transient reduction in melanoma mortality in Schleswig–Holstein, and the possible contribution of other factors needs to be evoked. A first possibility could be random variation in trends because of the relatively small number of melanoma deaths occurring each year in Schleswig–Holstein. For each sex, about 42 melanoma deaths per year were reported in Schleswig–Holstein,\textsuperscript{7} which resulted in important fluctuations in the estimation of mortality rate (figure 1).

Another possibility could be a bias in the ascertainment of the causes of death. Certifications of the causes of

\begin{table}[h]
\centering
\caption{Melanoma mortality annual per cent change for all ages for men and women between 1980 and 2012 and in the past 5 years for Germany and surrounding countries}
\begin{tabular}{|l|c|c|c|c|}
\hline
\textbf{Country} & \textbf{Men} & \textbf{Women} & & \\
 & \textbf{Annual per cent change (%) (95\% CI)} & \textbf{Annual per cent change (%) (95\% CI)} & & \\
 & 1980–2012 & 2008–2012 & & \\
\hline
Germany & 0.44 (0.26 to 0.62) & 2.57 (–0.10 to 5.24) & –0.15 (–0.30 to 0.00) & 0.02 (–1.79 to 1.82) \\
Czech Republic* & –0.55 (–0.91 to –0.20) & 0.65 (–4.57 to 5.88) & –0.90 (–1.41 to –0.39) & –0.25 (–4.40 to 3.90) \\
Poland & 2.70 (2.43 to 2.97) & 1.19 (–0.64 to 3.01) & 1.62 (1.28 to 1.97) & 1.28 (–0.85 to 3.42) \\
Denmark† & 0.60 (0.17 to 1.03) & –1.70 (–7.51 to 4.11) & –0.11 (–0.64 to 0.41) & –1.70 (–9.61 to 6.21) \\
Austria & 0.84 (0.40 to 1.28) & –0.06 (–1.17 to 1.04) & 0.29 (–0.11 to 0.69) & 2.17 (–7.11 to 11.5) \\
Belgium‡ & 2.10 (1.77 to 2.60) & –2.74 (–7.18 to 1.71) & 2.22 (1.74 to 2.84) & –1.17 (–5.74 to 3.41) \\
France‡ & 2.20 (2.03 to 2.37) & 1.96 (–1.60 to 5.51) & 1.23 (0.97 to 1.49) & 2.64 (–9.63 to 14.9) \\
The Netherlands & 2.54 (2.31 to 2.76) & 1.04 (–3.34 to 5.42) & 1.79 (1.48 to 2.10) & –0.82 (–6.33 to 4.69) \\
Switzerland‡ & 0.33 (–0.06 to 0.72) & 4.28 (–3.85 to 12.4) & –0.37 (–0.78 to 0.04) & –1.21 (–3.11 to 0.69) \\
\hline
\end{tabular}
\end{table}

In bold, significant trends. *Data available from 1986. †Data available until 2011. ‡Data available until 2010.
Three-quarters of physicians established in Schleswig–Holstein with outpatient activities (including surgeons, gynaecologists, urologists) participated in the SCREEN project. The SCREEN project benefited from intense mass media coverage. Within this context, we hypothesise that doctors practising in Schleswig–Holstein would have under-reported melanoma as the underlying cause of death. Such a bias is very likely because the SCREEN project was not a randomised controlled trial with blinding of cause of death assessors for the screening status of subjects. In addition, doctors were the entry point of participants in the SCREEN project; they were entitled to perform TBSE, and they were motivated by a financial incentive for each TBSE. The combined effect of these factors could have contributed to inducing a systematic bias in the causes of death reported on death certificates.

Unbiased ascertainment of causes of death is a challenge in studies having death due to a specific disease as the principal outcome. Even randomised trials on cancer screening are not immune to ascertainment bias. For instance, in the Swedish trials on breast cancer screening, cause of death committees or doctors completing death certificates knew or could guess which women had been invited to screening. A still ongoing controversy is to know whether the absence of true blinding of cause of death assessors may have introduced bias in the results of these trials.
CONCLUSION
The analysis of trends of melanoma mortality in Germany and in Schleswig–Holstein does not provide evidence that skin cancer screening is effective for preventing melanoma death. We hypothesise that a highly plausible reason for the transient decline in melanoma mortality reported in Schleswig–Holstein after screening start would be that the SCREEN project altered the way doctors reported the causes of death. If this hypothesis turned out to be grounded, then the German skin cancer screening programme would no longer be justified. The lack of a comprehensive evaluation is a major failure of the German screening programme.

Contributors MB, PA and SG contributed to the conception of the study, as well as to the acquisition, analysis and interpretation of data for the manuscript. They drafted the manuscript and revised it critically. All the authors gave their final approval of the version to be published.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided

REFERENCES
1. Lakhani NA, Saraiya M, Thompson TD, et al. Total body skin examination for skin cancer screening among US adults from 2000 to 2010. Prev Med 2014;61:75–80.
2. Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012;66:201–11.
3. Waldmann A, Nolte S, Weinstock MA, et al. Skin cancer screening participation and impact on melanoma incidence in Germany—an observational study on trends in regions with and without population-based screening. Br J Cancer 2012;106:370–4.
4. Anders MP, Nolte S, Waldmann A, et al. The German SCREEN project—design and evaluation of the communication strategy. Eur J Public Health 2015;25:150–5.
5. Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. J Am Acad Dermatol 2014;71:611.e1–10.
6. Mayer JE, Swetter SM, Fu T, et al. Screening, early detection, education, and trends for melanoma: current status (2007–2013) and future directions: Part II. Screening, education, and future directions. J Am Acad Dermatol 2014;71:611.e1–10.
7. Geller AC, Greinert R, Sinclair C, et al. A nationwide population-based skin cancer screening in Germany: proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009). Cancer Epidemiol 2010;34:355–8.
8. Eismen N, Waldmann A, Garbe C, et al. Development of a microsimulation of melanoma mortality for evaluating the effectiveness of population-based skin cancer screening. Med Decis Making 2015;35:243–54.

Table 2 Melanoma mortality annual per cent change in the most recent uninterrupted trend identified by joinpoint regression by age group in Germany and surrounding countries

| Country                  | Below 60 years | 60–74 Years | 75 Years and above |
|--------------------------|----------------|------------|-------------------|
|                          | Annual per cent change % (95% CI) | Period | Annual per cent change % (95% CI) | Period | Annual per cent change % (95% CI) | Period |
| Men                      |                |            |                    |        |                                |        |
| Germany                  | −0.9 (−1.2 to −0.7) | 1980–2012 | 1.4 (0.6 to 2.1) | 1998–2012 | 1.6 (1.1 to 2.1) | 1992–2012 |
| Czech Republic*          | −2.8 (−3.5 to −2.1) | 1986–2012 | −0.3 (−0.9 to 0.4) | 1986–2012 | 2.1 (1.4 to 2.8) | 1986–2012 |
| Poland                   | −0.4 (−1.6 to 0.7) | 1996–2012 | 3.1 (2.7 to 3.5) | 1983–2012 | 5.6 (4.9 to 6.2) | 1980–2012 |
| Denmark†                 | −1.2 (−1.8 to −0.6) | 1980–2011 | 1.6 (0.9 to 2.2) | 1980–2011 | 2.8 (1.6 to 4.1) | 1980–2011 |
| Austria                  | −0.9 (−1.5 to −0.3) | 1980–2012 | 1.1 (0.5 to 1.7) | 1980–2012 | 1.5 (−0.3 to 3.3) | 1990–2012 |
| Belgium‡                 | 2.2 (1.5 to 3.0) | 1980–2010 | 2.3 (1.7 to 2.9) | 1980–2010 | 1.7 (0.8 to 2.7) | 1980–2010 |
| France‡                  | 1.1 (0.9 to 1.4) | 1980–2010 | 2.2 (1.7 to 2.6) | 1990–2010 | 3.4 (2.9 to 3.9) | 1980–2010 |
| The Netherlands          | 1.2 (0.8 to 1.5) | 1980–2012 | 3.9 (3.5 to 4.4) | 1980–2012 | 3.9 (3.2 to 4.7) | 1980–2012 |
| Switzerland‡             | −1.3 (−2.1 to −0.6) | 1980–2010 | 0.8 (−0.0 to 1.2) | 1980–2010 | 0.1 (−1.6 to 1.9) | 1991–2012 |
| Women                    |                |            |                    |        |                                |        |
| Germany                  | 0.3 (−0.2 to 0.8) | 1997–2012 | −0.4 (−0.8 to −0.0) | 1988–2012 | 1.0 (0.8 to 1.3) | 1980–2012 |
| Czech Republic*          | −2.2 (−3.0 to −1.4) | 1986–2012 | −0.4 (−1.1 to 0.3) | 1986–2012 | 6.4 (−2.0 to 15.5) | 2007–2012 |
| Poland                   | −0.5 (−1.0 to 0.0) | 1987–2012 | 2.0 (1.7 to 2.4) | 1980–2012 | 3.5 (3.1 to 4.0) | 1980–2012 |
| Denmark†                 | −1.7 (−2.5 to −0.8) | 1980–2011 | 0.6 (−0.2 to 1.3) | 1980–2011 | 2.0 (1.4 to 2.6) | 1980–2011 |
| Austria                  | −0.4 (−1.0 to 0.3) | 1980–2012 | 0.3 (−0.3 to 0.9) | 1980–2012 | −0.5 (−2.1 to 1.1) | 1994–2012 |
| Belgium‡                 | 1.0 (0.1 to 2.0) | 1988–2010 | 0.8 (−0.6 to 2.3) | 1988–2010 | 2.2 (1.4 to 3.0) | 1980–2010 |
| France‡                  | 0.5 (0.1 to 0.9) | 1980–2010 | 0.4 (−0.7 to 1.4) | 1994–2010 | 2.2 (1.8 to 2.6) | 1980–2010 |
| The Netherlands          | 1.2 (0.8 to 1.6) | 1980–2012 | 2.3 (1.7 to 2.9) | 1980–2012 | 2.8 (2.4 to 3.3) | 1980–2012 |
| Switzerland‡             | −1.4 (−2.0 to −0.8) | 1980–2010 | 0.2 (−0.5 to 0.9) | 1980–2010 | 0.1 (−0.7 to 0.9) | 1982–2010 |

In bold, significant trends.
*Data available until 1986.
†Data available until 2011.
‡Data available until 2010.
§Statistically significant increase of melanoma mortality.
¶Statistically significant decrease of melanoma mortality.
9. Kornek T, Schäfer I, Reusch M, et al. Routine skin cancer screening in Germany: four years of experience from the dermatologists’ perspective. *Dermatology* 2012;225:289–93.

10. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID). http://www.gekid.de (accessed 10 Dec 2014).

11. Gesundheitsberichterstattung des Bundes. www.gbe-bund.de (accessed 15 Dec 2014).

12. National Cancer Institute. Joinpoint Regression Program, Version 3.5.4. Statistical Research and Applications Branch, National Cancer Institute, August 2012.

13. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000;19:335–51.

14. Breitbart EW, Choudhury K, Anders MP, et al. Benefits and risks of skin cancer screening. *Oncol Res Treat* 2014;37(Suppl 3):38–47.

15. Debating Population vs. Genetic Screening for Melanoma. *Oncology Times* 2015;37:9–10.

16. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. *J Natl Cancer Inst* 1999;91:1033–9.

17. USSG. US Department of Health and Human Services. The Surgeon General’s call to action to prevent skin cancer. Washington DC: US Dept of Health and Human Services, Office of the Surgeon General, 2014. http://www.surgeongeneral.gov/library/calls/prevent-skin-cancer/ (accessed 15 Dec 2014).

18. Eisemann N, Waldmann A, Katalinic A. Imputation of missing values of tumour stage in population-based cancer registration. *BMC Med Res Methodol* 2011;11:129.

19. Das C. Death certificates in Germany, England, The Netherlands, Belgium and the USA. *Eur J Health Law* 2005;12:193–211.

20. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *Lancet* 2001;358:1340–2.